Integrating Value Assessment Into Discussions About the Price of Cancer Drugs

Demandas judiciais por medicamentos antineoplásicos: a ponta de um iceberg?

“…However, these innovations have also been widely pointed out in the literature as one of the main causes for the accelerated increase in the costs of oncological care worldwide [19][20][21] . A study by Brunnel 22 warned that 90% of all antineoplastic drugs approved by the Food and Drug Administration (FDA) for use in the USA cost more than US$ 20,000 for a 12-week treatment. Fojo and Grady 20 expanded the discussion by warning about the association of few clinical benefits when compared to the high costs related to the treatment of cancer, mainly leveraged by the introduction of biotechnology drugs.…”